Fig. 4. CD27+IgD+ B cell amounts are increased after treatment of human SLE. (A) Flow cytometry assessment of CD27+IgD+ B cell levels pre-treatment and at 4 weeks post-treatment initiation. (B) SLEDAI scores before and after treatment in SLE patients (n=12). (C) CD27+IgD+ B cell percentages in SLE patients before and after treatment (n=12). (*P<0.05, **P<0.01).